Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: a longitudinal registry-based analysis.

IF 7.1 1区 医学 Q1 HEMATOLOGY
Priya H Marathe, Anne S Reiner, Dana Bossert, Allison M Sigler, Deanna Fournier, Kathleen Brewer, Gaurav Goyal, Thomas M Atkinson, Jun J Mao, Katherine S Panageas, Eli L Diamond
{"title":"Symptoms, unmet needs, and quality of life in Erdheim-Chester disease: a longitudinal registry-based analysis.","authors":"Priya H Marathe, Anne S Reiner, Dana Bossert, Allison M Sigler, Deanna Fournier, Kathleen Brewer, Gaurav Goyal, Thomas M Atkinson, Jun J Mao, Katherine S Panageas, Eli L Diamond","doi":"10.1182/bloodadvances.2024015659","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Measurement of patient-reported outcomes (PROs) and health-related quality of life (HrQOL) are crucial for comprehensive, patient-centered cancer care. Both PROs and HrQOL have been understudied in patients with Erdheim-Chester disease (ECD), a rare cancer with protean manifestations, dense symptomatology, and frequent diagnostic delay. We sought to evaluate the longitudinal evolution of symptom burden and unmet supportive care needs in patients with ECD, and to identify associations between these PROs and HrQOL. A registry-based cohort of patients with ECD completed a PRO battery including the Functional Assessment of Cancer Therapy-General (FACT-G) and other validated PRO measures. Descriptive statistics were used to characterize the distribution of PROs and FACT-G scores; PROs were modeled by univariable linear regression with FACT-G total score as the dependent variable at (1) registry enrollment and (2) 12-month time points. Changes in FACT-G total score (the difference between the 12-month and enrollment scores) were correlated with changes in PROs using univariable linear regression analysis. In 158 patients, mean total FACT-G was 70.8, lower than observed across multiple cancer cohorts. Higher levels of pain and fatigue, presence of neurologic symptoms, and greater number of unmet needs were all associated with worse HrQOL. Improvement in pain, fatigue, and unmet needs over 12 months was significantly associated with improvement in HrQOL. In patients with ECD, HrQOL is substantially diminished, even when considering other patients with cancer. Mitigation of symptoms and addressing unmet supportive care needs represent opportunities for intervention to improve HrQOL in ECD.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"4415-4424"},"PeriodicalIF":7.1000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405683/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024015659","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Measurement of patient-reported outcomes (PROs) and health-related quality of life (HrQOL) are crucial for comprehensive, patient-centered cancer care. Both PROs and HrQOL have been understudied in patients with Erdheim-Chester disease (ECD), a rare cancer with protean manifestations, dense symptomatology, and frequent diagnostic delay. We sought to evaluate the longitudinal evolution of symptom burden and unmet supportive care needs in patients with ECD, and to identify associations between these PROs and HrQOL. A registry-based cohort of patients with ECD completed a PRO battery including the Functional Assessment of Cancer Therapy-General (FACT-G) and other validated PRO measures. Descriptive statistics were used to characterize the distribution of PROs and FACT-G scores; PROs were modeled by univariable linear regression with FACT-G total score as the dependent variable at (1) registry enrollment and (2) 12-month time points. Changes in FACT-G total score (the difference between the 12-month and enrollment scores) were correlated with changes in PROs using univariable linear regression analysis. In 158 patients, mean total FACT-G was 70.8, lower than observed across multiple cancer cohorts. Higher levels of pain and fatigue, presence of neurologic symptoms, and greater number of unmet needs were all associated with worse HrQOL. Improvement in pain, fatigue, and unmet needs over 12 months was significantly associated with improvement in HrQOL. In patients with ECD, HrQOL is substantially diminished, even when considering other patients with cancer. Mitigation of symptoms and addressing unmet supportive care needs represent opportunities for intervention to improve HrQOL in ECD.

Abstract Image

厄德海姆-切斯特病的症状、未满足的需求和生活质量:一项基于纵向登记的分析
患者报告结果(PROs)和健康相关生活质量(HrQOL)的测量对于全面的、以患者为中心的癌症治疗至关重要。对Erdheim-Chester病(ECD)患者的PROs和HrQOL进行了充分的研究,ECD是一种罕见的癌症,具有变异性的表现,密集的症状,经常诊断延迟。我们试图评估ECD患者症状负担和未满足的支持性护理需求的纵向演变,并确定这些PROs与HrQOL之间的关联。基于登记的ECD患者队列完成了PRO系列,包括癌症治疗功能评估(FACT-G)和其他经过验证的PRO措施。采用描述性统计来表征PROs和FACT-G分数的分布;PROs采用单变量线性回归模型,在(1)注册登记和(2)12个月时间点以FACT-G总分为因变量。采用单变量线性回归分析,FACT-G总分的变化(12个月与入组评分的差异)与pro的变化相关。在158例患者中,平均总FACT-G为70.8,低于多个癌症队列的观察结果。较高程度的疼痛和疲劳、神经系统症状的存在以及大量未满足的需求都与较差的HrQOL相关。12个月内疼痛、疲劳和未满足需求的改善与HrQOL的改善显著相关。在ECD患者中,即使考虑到其他癌症患者,HrQOL也大大降低。缓解症状和解决未满足的支持性护理需求是改善ECD患者HrQOL的干预机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood advances
Blood advances Medicine-Hematology
CiteScore
12.70
自引率
2.70%
发文量
840
期刊介绍: Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信